A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts ; volume:10 ; number:1 ; day:3 ; month:7 ; year:2020 ; pages:1-13 ; date:12.2020
EJNMMI Research ; 10, Heft 1 (3.7.2020), 1-13, 12.2020
- Urheber
-
Paquette, Michel
Phoenix, Serge
Lawson, Christine
Guérin, Brigitte
Lecomte, Roger
Tai, Lee-Hwa
Turcotte, Éric E.
Leyton, Jeffrey V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-020-00656-8
- URN
-
urn:nbn:de:101:1-2020083119220545542026
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Paquette, Michel
- Phoenix, Serge
- Lawson, Christine
- Guérin, Brigitte
- Lecomte, Roger
- Tai, Lee-Hwa
- Turcotte, Éric E.
- Leyton, Jeffrey V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Patient-derived xenografts as preclinical neuroblastoma models
Patient-derived xenografts: a relevant preclinical model for drug development
Dual HER2 blockade: preclinical and clinical data
Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies
Erratum to: Dual HER2 blockade: preclinical and clinical data
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
Affibody-based molecular probe 99m Tc-(HE) 3 Z HER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer
Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine
Tracer
Patient-derived xenografts as preclinical neuroblastoma models
Patient-derived xenografts: a relevant preclinical model for drug development
Dual HER2 blockade: preclinical and clinical data
Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies
Erratum to: Dual HER2 blockade: preclinical and clinical data
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
Affibody-based molecular probe 99m Tc-(HE) 3 Z HER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer
Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine
Tracer
Patient-derived xenografts as preclinical neuroblastoma models
Patient-derived xenografts: a relevant preclinical model for drug development
Dual HER2 blockade: preclinical and clinical data
Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies
Erratum to: Dual HER2 blockade: preclinical and clinical data
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
Affibody-based molecular probe 99m Tc-(HE) 3 Z HER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer
Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine